Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00358358 · ClinicalTrials.gov registry record · Phase 4
Chronic Obstructive Pulmonary Disease Endpoints Study
A Phase 4 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 163
- Enrollment target
NCT00358358 is a Phase 4 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 163 participants.
The verdict
NCT00358358, a Phase 4 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 163 participants
- Enrollment target
Study Summary
This study will last for approximately 14 weeks and will involve 5 visits. The study is being carried out to look at different ways of measuring the effect of drug treatment on COPD. COPD is a respiratory disease which can affect your breathing and daily life. Symptoms of COPD can include breathlessness, cough, and wheeze. COPD varies enormously from patient to patient. The effects of drug treatment are usually measured by conducting lung function tests (breathing tests) using a machine called a spirometer but this does not always provide a complete picture of how well your COPD is responding. In this study we therefore want to look at new and more sensitive ways of measuring COPD. The results of this research will help in the assessment of new drugs for COPD in the future.
Interventions
- DRUG Fluticasone Propionate/Salmeterol 500/50mcg combination
- DRUG Fluticasone Propionate 500mcg
- DRUG Salmeterol 50mcg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2006-03 |
| Est. Completion | 2007-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00358358
The ClinicalTrials.gov registry entry for NCT00358358 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Fluticasone Propionate/Salmeterol 500/50mcg combination is the first listed.
NCT00358358 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00358358 about?
NCT00358358 is a clinical study titled "Chronic Obstructive Pulmonary Disease Endpoints Study". This study will last for approximately 14 weeks and will involve 5 visits. The study is being carried out to look at different ways of measuring the effect of drug treatment on COPD. COPD is a respiratory disease which can affect your breathing and daily life. Symptoms of COPD can include breathless...
What is the current status of trial NCT00358358?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 163 participants. The study started on 2006-03. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00358358?
The interventions under investigation include: Fluticasone Propionate/Salmeterol 500/50mcg combination (DRUG), Fluticasone Propionate 500mcg (DRUG), Salmeterol 50mcg (DRUG).
Who is sponsoring clinical trial NCT00358358?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.